drugset / Trial / NCT04106492
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of SQ3370 in patients with advanced solid tumors.
Timeline
- Start
- 2020-08-01
- Primary completion
- 2023-09-07
- Completion
- 2023-09-07
Outcome
Outcome not reported
Stopped: “Sponsor's decision”
Publications
- Srinivasan S, Yee NA, Aleckovic M, Zakharian M, Mahmoodi A, Wagner S, Nguyen TH, Chawla SP, Guminski AD, Mejia Oneto JM. Development of a First-in-Class Click Chemistry-Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial. Clin Cancer Res. 2025 Sep 2;31(17):3662-3677. doi: 10.1158/1078-0432.CCR-24-2539.
- Srinivasan S, Yee NA, Zakharian M, Aleckovic M, Mahmoodi A, Nguyen TH, Mejia Oneto JM. SQ3370, the first clinical click chemistry-activated cancer therapeutic, shows safety in humans and translatability across species. bioRxiv [Preprint]. 2023 Mar 29:2023.03.28.534654. doi: 10.1101/2023.03.28.534654.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SQL70 | Other / unclassified | 10 ml | Other |
| Subject | SQL70 | Other / unclassified | 20 ml | Other |
| Subject | SQP33 | Other / unclassified | 8 mg/m2 | Intravenous |
| Subject | SQP33 | Other / unclassified | 16 mg/m2 | Intravenous |
| Subject | SQP33 | Other / unclassified | 32 mg/m2 | Intravenous |
| Subject | SQP33 | Other / unclassified | 58 mg/m2 | Intravenous |
| Subject | SQP33 | Other / unclassified | 85 mg/m2 | Intravenous |
| Subject | SQP33 | Other / unclassified | 125 mg/m2 | Intravenous |
| Subject | SQP33 | Other / unclassified | 185 mg/m2 | Intravenous |
| Subject | SQP33 | Other / unclassified | 250 mg/m2 | Intravenous |
| Subject | SQP33 | Other / unclassified | 315 mg/m2 | Intravenous |
| Subject | SQP33 | Other / unclassified | 500 mg/m2 | Intravenous |